These domains are for sale: 

(“pandemia” means pandemic in 14 languages: Spanish, Portuguese, Italian, Polish, Finnish, Hungarian, Czech, Slovak, Albanian, Catalan, Kiswaili, Lingala, Ilokano and Latin)

All these 12 domains for 39 thousand USD (negotiable). You can buy them also individually.

  •      5000 USD
  •       6000 USD
  •             3800 USD
  •             5500 USD
  •             6000 USD
  •   6000 USD
  •        6000 USD
  •   600 USD
  •           200 USD
  • all three domains together   9900 USD

All these domain re-direct to  I’m receiving more than 10 thousand visitors a day since 22 March 2020. I suppose I’ll reach 1 Million visitors within end of April 2020. Advanced Page Visit Counter is installed, I can provide data if requested.

WEBSITE  CONTENTS (data update as 25th March 2am UTC): 

  1. Coronavirus therapy, vaccine and drugs 

  2. When and how will Covid-19 pandemic end?

  3. Where to find Chloroquine and Tocilizumab?

  4. LIST OF COUNTRIES BY CASE FARALITY RATE for Coronavirus (rate of deaths) update 25th March

All the contents are original and based on official sources (which are linked).

1. Coronavirus therapy, vaccine and treatments

Most effective drugs available, vaccines and mechanical ventilation machines for Covid-19

By G. Z.  – Venezia -12th March 2020 – Completely update as 24th March 2020

Remdesivir (Gilead Sciences Inc.)

Although experimental , the injectable drug Remdesivir, made by Gilead Sciences, is an antiviral effective against a wide range of viruses (broad-spectrum). Francis Collins, director of the National Institutes of Health, thinks it can be efficacy against COVID-19.
This drug is still experimental then it is not availalbe in any pharmacy but it’s currently given to patients in many hospitals in China, Taiwan, US and Europe.
Wuhan Institute of Virology, Washington state health officials and Spallanzani Hospital in Rome confirmed important effictiveness of Remdesivir antiviral in many patients.
Gilead Sciences Thursday 27th February 2020 declared they launched remdesivir’s Phase III trials in Covid-19 patients. This phase of clinical research usually last way more than an year but Gilead Sciences on Twitter declared that due to the international health emergency the testing will be much faster and in case of success quickly could begin the last Phase IV also known as “confirmatory trial”.
Gilead Sciences in the last weeks is doing very well in the Nasdaq moving from 65 dollars (beginning of February) to 85 dollar (19th March 2020).

Chloroquine phosphate, an old drug for the treatment of malaria, is shown to have efficacy against COVID-19 associated pneumonia in multicenter clinical trials conducted in China.
A number of subsequent clinical trials have been quickly conducted in China to test the efficacy of chloroquine or hydroxychloroquine in the treatment of severe COVID-19 associated pneumonia in more than 10 hospitals in Wuhan, Jingzhou, Guangzhou, Beijing, Shanghai, Chongqing, and Ningbo. Patients are getting 400 milligrams a day for five days.
In fact results from more than 100 patients have demonstrated that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course according to the news briefing
Given these findings, a conference was held on February 15, 2020; participants including experts from government and regulatory authorities and organizers of clinical trials reached an agreement that chloroquine phosphate has potent activity against COVID-19. The drug is recommended for inclusion in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of China.

Tocilizumab (Actemra)

The National Institute for Cancer “Pascale” in Naples (Italy) on 19th March 2020 started testing the Tocilizumab, an immunosuppressive drug, which is mainly used and approved drug for the treatment of rheumatoid arthritis. This test phase have been extended to 4 more hospitals in Italy. China’s National Health Commission and the Italian physician Paolo Ascierto reported that Tocilzumad have be effective in some severe cases of Novel Coronavirus. 

The US FDA (Food and Drug administration) the 23rd March authorized the beginning of the double-blind phase III clinical trial of Tocilizumad for the treatment of patients with severe Covid-19.

Avigan (Favipiravir)

Avigan (produced by Fujifilm Toyama Chemical, Tokyo) is an anti-viral drug approved in Japan in 2014 to treat influenza. In February it was authorized as experimental treatment for Covid-19 pneumonia. After a test on 340 patinents in Wuhan, the Chinese Science and technology ministry Zhang Xinmin declared it showed clearly effectiveness. Avigan seems effective in preventing replication of the Sars-coV-2, the coronavirus, and improving lung contitions.

AIFA (Italian medicine agency, the pharmaceutical Italian regulatory institution) on 23rd March reported that the drug is not approved in Europe and USA and there not so far clinical studies demostrating its efficacy to treat Covid-19 so far. But based on some small non randomized clinical studies on Avigan as a treatment to the Coronavirus, AIFA approved  a testing and research program to evaluate its efficacy 

Vaccines for COVID-19

Update as 25th March 2020

Many scientists and drug companies are developing vaccines that address COVID19, the disease caused by the novel coronavirus. Work is progressing fast but since they starting essentially from scratch to make the vaccine, so it will takes some time. Probably it will be availalbe around February 2021 if we’re lucky or a few months later.
The developing of a vaccine involves making copies of one part of the virus (in this case, the bit that the novel coronavirus uses to infiltrate cells). Then, the immune system of the person who receives the vaccine makes antibodies that are able to prevent the Coronavirus to infiltrate and reproduce itself in our body. A new Italian study states released 25th March that COVID-19 virus is slow to mutate, then any vaccine will be probably effective worldwide for a relative long period of time (more than one year).

MODERNA Inc, a pharmaceutical company from Cambridge (Massachusetts) is so far probably the one who did the most. In the last week of February it already developed a vaccine and the 16th March began the Phase I trial, it is testing the vaccine on humans, injekcting it in healthy participants. All the testing phases usually last much longer than the developing ot the vaccine itself (probably around 10 months or shorter) . After that if the test will be successful it will be necessary to produce it in large scale. MODERNA Inc announced on 23rd March that it might get EMERGENCY APPROVAL  this autumn for Covid19 vaccine for health care workers.
But wide availability is still estimated happening between March and August 2021.

ANGES Inc, a biopharmaceutial company from Osaka (Japan), and Osaka University announcend on the 24 March that they developed a DNA vaccine for SARS-coV-2 (it is the Covid-19 virus, it can be called both ways Sar-cov-2 and Covid-19 virus). On the Tokyo stock market Anges rise 19% after the announcement. It took them less than 3 weeks to develp the vaccine but it is the testing phases  which need much more time (more than 10 months) to be completed. Then there is the need to scale production but good news the DNA vaccines like this one made with inactivated virus can be produced faster than the vaccines based on proteins.

CureVac AG, a German biopharmaceutical company based in Tubingen near Stutgart, specialized in mRNA therapies and vaccines, declared on 23th March they will be ready with the COVID-19 mRNA vaccine by next fall. Then they will need to do the animal testing and human trials as usual. This means that the company for now is in late if compared to ANGES INC and MODERNA which already developed a vaccine. Anyway the US President Donald J. Trump declared he made an important offer to acquire CureVac (Welt am Sontag newspaper wrote about 1 billion USD). CureVac reported they didn’t receive any formal offer for now. German economy minister Peter Altmaier showed irritation about this “incident” answering that “Germany is not for sale”.

Plasma from survivors

A person who gets infected with a virus but beats it has blood swarming with antibodies to the germ. It’s been shown that collecting blood plasma from survivors and infusing it into another person can sometimes be life-saving. While plasma is not certain to work, more than 27,000 people are already listed as recovered from coronavirus in China, so there could be an ample number of donors. Doctors in Shanghai are among those trying plasma infusions.

TAKEDA PHARMACEUTICAL (it is the biggest pharmaceutical company of ALL Asia, founded the 12th June 1781, yes you read correctly, 1781, in Osaka but now headquartered in Tokyo) in the beginning of March 2020 reported that it is working on a plasma derived treatment using Hyperimmune Globuline which is already proved to be effective in severe acute viral respiratory diseases. 

2. When and how will Coronavirus pandemic end?

By G. Z. – Venezia – 17th March 2020 23:00 UTC – Update 21 March

Summer will weaken Covid-19 pandemic in the Northern hemisphere. Meanwhile quarantine will be high efficacy. Remdesivir will be maybe used as Pre-exposure Prophylaxis. Vaccines will be ready not before January 2021. Also molecules already known could play a big role, SUMMIT (IBM Artificial Intelligence) doing a good work about it.

Watching what happened in China and what is happening in Italy I’m very optimistic, when you put a whole nation in quarantine you end the New Coronavirus ( Covid-19 ) spread for your own country.
But then if some countries abroad fail to contain the infection, you will re-import the virus.
Some foreigners will come to your country, given the globalized world and new Coronavirus outbreaks will be reborn…
So once the Coronavirus has been eradicated with the quarantine you will need to keep the country isolated from other countries ?? very hard to do.

So maybe only summer will save us.
Although some virologists, epimediologists and even the WHO (World Health Organization) claim there is no evidence that the heat actually stops the Coronavirus ( Covid-19 ) by looking at how other Coronaviruses behave in the heat (there are various studies about how heat affect those virus) and also looking at the world map of infections you can see that there have been relatively few Coronavirus cases in countries that are hot at this time of year (Australia, the Americas from Mexico down, Thailand and Vietnam that even have millions of Chinese tourists).

Summer 2020 should therefore will not be that bad.
But then in October the Covid 19 will return, at first slowly and then more quickly the outbreaks emerge … Of course we will all be more careful, we will take some precautions but it will be hard to contain it again.

In 2021 vaccines will be ready and the problem will be solved forever (except for particular mutations of the coronavirus). Vaccines will arrive if they are early in January / February 2021, if it takes longer in the summer of 2021.

Before the vaccine, the most concrete hope is if we can do a Pre-exposure Prophylaxis (PrEP) using Remdesivir (it is a broad spectrum antiviral that was created to fight Ebola virus).
Remdesivir is still in the experimental phase III, it needs a few months or more to be ready for use on a large scale, and there is hope that we can use it as a pre-exposure prophylaxis where therefore BEFORE the drug is administered and in more than 90% of cases, then you do not get sick.
If we cannot use Remdesivir successfully as a prophylaxis then you will have to suffer until the arrival of the actual vaccine and continue to use Chloroquine (an antimalarial), Tocilizumab (an anti-arthritis) or Remdesivir that anyway has an excellent effect even after contracting the Cornavirus (Covid 19) like the other two drugs mentioned.

3. Where to find Chloroquine and Tocilizumab?

You can find Chloroquine over the counter (without prescription) in UK under the name “Chloroquie phosphate tablets bp 250mg” (Leaflet). Chloroquine is available in many countries with its generic name (Chloroquine) or different brand names that you can read here in this list: Cadiquin and Emquin in India and Pakistan;  Alexoquine in Egypt, Clorochina Bayer in Italy, Plasmoquine in South Africa, Nivaquine in Switzerland, Aralen Hydrochloride in the United States, Savarine in France, Resochin in Germany and Austria, Malarivon in United Kingdom, Kutlu in Turkey.

Tocilizumad is available over the counter (without a prescription) in Turkey and in many other countries with its generic name (Tocilizumad) or other brand name here in the list: Actembra in Egypt, Actemra in China and Turkey, RoActemra in Slovenia, United Kingdom, Poland, Germany, France and Spain.

Case fatality rate of Coronavius

Venezia – 25th March 2020 21:00 UTC

The majority of cases have mild symptoms but some, mostly elderly with preexisting conditions, progress to severe Covid-19 pneumonia and multi-organ failure. The rate of deaths per number of diagnosed cases of Novel Coronavirus is on average 4.5% (calculated 25th March 2020), ranging from 0.2% in those under 20, to approximately 18% in those over 80 years old. The rate of  deaths will grow because some of the patients still sick (and they are the majority) will unfortunately dye rising the rate. In Italy so far we have the highest case fatality rate for Covid-19 which is 9.9% and the highest number of deaths (higher than China) which correspond at 25th March 2020 to 6820 victims. The reason why Italian mortality rate is so much higher in Italy depends on many factors, one is the Italian median age which is 45.5, one of the highest in the world. Other reason could depend on the testing system, in Italy we are testing only people showing strong symptoms and this metodology can easily led to getting an higher case fatality rate.

4. LIST OF COUNTRIES BY CASE FARALITY RATE for Covid-19 (rate of deaths covid19) 

By G. Z. – Update as 26th March 2020 4.00am UTC – data source

  • Italy        10.1%
  • Iran          7.7%
  • Spain        7.4%
  • Netherlands 5.6%
  • France      5.3%
  • UK             4.9%
  • China        4.0%
  • Belgium    3.6%
  • Japan         3.4%
  • Sweden     2.5%
  • Turkey      2.4%
  • Ecuador    2.4%
  • Brazil        2.3%
  • Denmark  2.0%
  • Portugal    1.4%
  • USA            1.4%
  • Switzerland 1.4%
  • S. Korea     1.4%
  • Poland       1.3%
  • Malaysia   1.1%
  • Canada      1.1%
  • Pakistan    0.8%
  • Luxembourg 0.6%
  • Ireland     0.6%
  • Germany  0.6%
  • Austria      0.5%
  • Norway     0.5%
  • Australia   0.4%
  • Czechia     0.4%
  • Chile          0.3%
  • Israel         0.2%

Countries not in the list have very small infected of Covid-19 (less than 1000 so the calculation of the rate could be very unprecise).

Copyright © 2020 – Mark Zanni

Contents Copyright © 2020 – G. Z., Venezia (Italy)

Cheapest accommodation near Venice Marco Polo Airport – Venice Lagoon House B&B